Suppr超能文献

静脉注射美托洛尔与地尔硫䓬用于非心脏、非胸科术后房颤的心率控制

Intravenous metoprolol versus diltiazem for rate control in noncardiac, nonthoracic postoperative atrial fibrillation.

作者信息

Personett Heather A, Smoot Dustin L, Stollings Joanna L, Sawyer Mark, Oyen Lance J

机构信息

Mayo Clinic-Rochester Methodist Hospital, Rochester, MN, USA.

出版信息

Ann Pharmacother. 2014 Mar;48(3):314-9. doi: 10.1177/1060028013512473. Epub 2014 Jan 9.

Abstract

BACKGROUND

Little guidance exists on effective management of postoperative atrial fibrillation (POAF) following noncardiac, nonthoracic (NCNT) surgery.

OBJECTIVES

The purpose of this study was to identify whether a difference exists between intravenous (IV) metoprolol and diltiazem when used to achieve hemodynamically stable rate control in POAF following NCNT surgery.

METHODS

This retrospective cohort study examined critically ill adult surgical patients experiencing POAF with rapid ventricular response. Inclusion in the metoprolol or diltiazem treatment group was determined by the initial rate control agent chosen by the prescriber. The primary end point was hemodynamically stable rate control, defined by heart rate (HR) <110 beats/min and blood pressure >90 mm Hg, maintained for 6 hours.

MAIN RESULTS

Patients on metoprolol (n = 66) and diltiazem (n = 55) were similar in age, comorbidities, surgical procedure distribution, acuity of illness, and home rate and rhythm control medications continued during hospitalization; 76% of diltiazem-treated patients achieved hemodynamically stable rate control, compared with only 53% of those receiving metoprolol (P = .005). Safety end points were similar between groups, including the portion requiring a new vasopressor or fluid bolus for hemodynamic support.

CONCLUSIONS

In NCNT surgery, patients with POAF, IV diltiazem more effectively controlled HR and hemodynamics compared with metoprolol. Results warrant further research into optimal medical management of POAF in this population using these 2 agents.

摘要

背景

关于非心脏、非胸部(NCNT)手术后房颤(POAF)的有效管理,几乎没有相关指导。

目的

本研究的目的是确定静脉注射美托洛尔和地尔硫䓬在用于非心脏非胸部手术后房颤的血流动力学稳定心率控制时是否存在差异。

方法

这项回顾性队列研究检查了患有快速心室反应的POAF的危重症成年外科患者。美托洛尔或地尔硫䓬治疗组的纳入由处方医生选择的初始心率控制药物决定。主要终点是血流动力学稳定的心率控制,定义为心率(HR)<110次/分钟且血压>90 mmHg,并维持6小时。

主要结果

接受美托洛尔(n = 66)和地尔硫䓬(n = 55)治疗的患者在年龄、合并症、手术程序分布、疾病严重程度以及住院期间继续使用的家庭心率和节律控制药物方面相似;接受地尔硫䓬治疗的患者中有76%实现了血流动力学稳定的心率控制,而接受美托洛尔治疗的患者中这一比例仅为53%(P = 0.005)。两组的安全性终点相似,包括需要新的血管升压药或液体推注以进行血流动力学支持的比例。

结论

在非心脏非胸部手术中,与美托洛尔相比,静脉注射地尔硫䓬能更有效地控制POAF患者的心率和血流动力学。结果值得进一步研究使用这两种药物对该人群POAF进行最佳药物管理。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验